Lipid profile of patients newly diagnosed with type 2 diabetes in Albania

2013 ◽  
Author(s):  
Florian Toti ◽  
Aldi Shehu ◽  
Kliti Hoti ◽  
Manjola Carcani ◽  
Adriana Lapardhaja ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lipid Profile ◽  
Newly Diagnosed

scholarly journals Value of simple clinical parameters to predict insulin resistance among newly diagnosed patients with type 2 diabetes in limited resource settings

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0248469
Author(s):  
Keddagoda Gamage Piyumi Wasana ◽  
Anoja Priyadarshani Attanayake ◽  
Thilak Priyantha Weerarathna ◽  
Kamani Ayoma Perera Wijewardana Jayatilaka
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Sri Lanka ◽  
Lipid Profile ◽  
Limited Resource ◽  
Small Sample ◽  
Clinical Parameters ◽  
Fasting Insulin ◽  
Newly Diagnosed

Background Insulin resistance (IR) has been considered as a therapeutic target in the management of type 2 diabetes mellitus (T2DM). Readily available, simple and low cost measures to identify individuals with IR is of utmost importance for clinicians to plan optimal management strategies. Research on the associations between surrogate markers of IR and routine clinical and lipid parameters have not been carried out in Sri Lanka, a developing country with rising burden of T2DM with inadequate resources. Therefore, we aimed to study the utility of readily available clinical parameters such as age, body mass index (BMI), waist circumference (WC) and triglyceride to high density lipoprotein cholesterol ratio (TG/HDL-C) in the fasting lipid profile in predicting IR in a cohort of patients with newly diagnosed T2DM in Sri Lanka. Methods and findings We conducted a community based cross sectional study involving of 147 patients (age 30–60 years) with newly diagnosed T2DM in a suburban locality in Galle district, Sri Lanka. Data on age, BMI, WC, fasting plasma glucose (FPG) concentration, fasting insulin concentration and serum lipid profile were collected from each subject. The indirect IR indices namely homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI) and McAuley index (MCA) were estimated. Both clinical and biochemical parameters across the lowest and the highest fasting insulin quartiles were compared using independent sample t-test. Linear correlation analysis was performed to assess the correlation between selected clinical parameters and indirect IR indices. The area under the receiver operating characteristic (ROC) curve was obtained to calculate optimal cut-off values for the clinical markers to differentiate IR. BMI (p<0.001) and WC (p = 0.01) were significantly increased whereas age (p = 0.06) was decreased and TG/HDL-C (p = 0.28) was increased across the insulin quartiles. BMI and WC were significantly correlated (p<0.05) with HOMA, QUICKI and MCA. Out of the clinical parameters, age showed a borderline significant correlation with QUICKI and TG/HDL-C showed a significant correlation only with MCA. The area under ROC of BMI was 0.728 (95% CI 0.648–0.809; p<0.001) and for WC, it was 0.646 (95% CI 0.559–0.734; p = 0.003). The optimized cut-off value for BMI and WC were 24.91 kg/m2 and 81.5 cm respectively to differentiate the patients with IR or ID. Study limitations include small sample size due to recruitment of patients only from a limited geographical locality of the country and not totally excluding of the possibility of inclusion of some patients with slowly progressive type 1 DM or Latent onset diabetes of adulthood from the study population. Conclusions The results revealed that there was a significant positive correlation between BMI, WC and HOMA while a significant negative correlation with QUICKI and MCA among the cohort of patients with newly diagnosed T2DM. The cut-off values of BMI and WC as 24.91 kg/m2 and 81.5 cm respectively could be used as simple clinical parameters to identify IR in newly diagnosed patients with T2DM. Our results could be beneficial in rational decision making in the management of newly diagnosed patients with T2DM in limited resource settings.

scholarly journals An open randomized study to compare effect of metformin versus acarbose monotherapy on glycemic control and lipid profile in newly diagnosed type 2 diabetes mellitus patients

2021 ◽  
Vol 9 (3) ◽  
pp. 755
Author(s):  
Ram A. Manda ◽  
Veena Verma ◽  
Krishna Biswas
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Randomized Study ◽  
Initial Therapy ◽  
Newly Diagnosed ◽  
Type 2 Dm ◽  
Control Serum

Background: Type 2 DM is one global health problem and a main cause of morbidity and mortality. It is epidemic in many industrialized and developing areas and is considered to be one of the most challenging health problems of the 21st century. Metformin and acarbose both are used as monotherapy and in combination with other anti-diabetes drugs for treatment of type 2 DM. There are very sparse evidences regarding comparative efficacy and safety of metformin versus acarbose, especially in Asian region. In addition to glycemic control, improvement in lipid profile, weight loss and post-prandial sugar level are important therapeutic objectives for better management of type 2 DM patients.Methods: In this study, 60 newly diagnosed type 2 DM were randomly assigned (1:1) to oral acarbose (titrated doses upto 300 mg daily) or oral metformin (titrated doses up to 2500 mg daily) monotherapy and were followed-up for 12 weeks for effects on glycaemic control [serum HbA1C, fasting blood sugar and post prandial sugar and serum LDL, HDL, triglycerides and total cholesterol.Results: Reduction in FBS, HbA1C and body weight was found significantly greater with metformin while acarbose yielded greater improvement in PPS, total cholesterol and triglyceride levels. Both metformin and acarbose yielded significant improvement in FBS, PPS, HbA1C, lipid profile and body weight after 12 weeks of therapy and yielded similar improvement in LDL and HDL levels.Conclusions: Acarbose can be considered as an alternative initial therapy in newly diagnosed type 2 diabetes patients, particularly those with isolated post-prandial hyperglycemia and those who are intolerant to metformin therapy. 

scholarly journals EFFECTS OF A COMBINATION THERAPY WITH ATORVASTATIN AND METFORMIN ON THE GLYCEMIC CONTROL AND ADIPOSITY INDICES IN NEWLY DIAGNOSED OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PILOT STUDY

2018 ◽  
Vol 11 (12) ◽  
pp. 209
Author(s):  
Samer Shukur Mohammed ◽  
Wael Waleed Mustafa ◽  
Saad Abdulrahman Hussain
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Visceral Adiposity Index ◽  
Newly Diagnosed ◽  
Adiposity Index ◽  
Adiposity Indices

Objective: In many type 2 diabetes mellitus (T2DM) patients, metformin is prescribed concomitantly with hypolipidemic agents, particularly statins. Meanwhile, variability in response to metformin is one of the most important problems in the efficacy of this combination. The present study aims to evaluate the effect of adding atorvastatin with metformin on the glycemic control, adiposity indices, and lipid profile of overweight patients newly diagnosed with type T2DM.Methods: A total of 50 overweight patients with T2DM were allocated into two groups, the first one received 850 mg/day of sustained release metformin and the second group received 10 mg/day atorvastatin in addition to the metformin. The patients were followed for 90 days through evaluating fasting serum glucose (FSG), glycated hemoglobin (HbA1c), body mass index (BMI), visceral adiposity index (VAI), and the lipid profile at baseline and after 90 days. In addition, the safety of the protocol was monitored through the evaluation of the renal and liver functions.Results: HbA1c, FSG, BMI, and VAI values were significantly decreased in both treatment groups compared with baseline. Meanwhile, the combination improves all the lipid profile components with respect to the baseline. No significant differences reported between the two groups regarding all the measured parameters. The addition of atorvastatin produced a slight but significant negative impact on the renal and liver functions.Conclusion: Addition of 10 mg/day atorvastatin with metformin in the treatment of newly diagnosed T2DM overweight patients did not produce significant improvement in glycemic control, adiposity index, and lipid profile compared with the use of metformin alone.

Sign in / Sign up

Export Citation Format

Share Document